Vladivostok |September 7,2025|SKY LINK TIMES|
In a landmark medical development, Russian scientists have announced that a new cancer vaccine named Enteromix is now ready for clinical use after years of research and trials. The breakthrough was unveiled by Veronika Skvortsova, head of Russia’s Federal Medical and Biological Agency (FMBA), during the 10th Eastern Economic Forum held in Vladivostok.
What Is Enteromix?
Enteromix is based on mRNA technology, the same approach used in several COVID-19 vaccines. Unlike traditional vaccines that use weakened viruses, mRNA vaccines teach the body’s cells to produce proteins that trigger a targeted immune response. In this case, the response is directed against cancer cells.
Results From Years of Trials of this cancer vaccine
According to Skvortsova, Enteromix underwent three years of mandatory preclinical trials, proving to be both safe and effective.
🔸Tumor reduction: In some cases, tumors shrank or slowed growth by 60% to 80%, depending on cancer type.
🔸Survival benefits: Test subjects also showed improved survival rates compared to untreated groups.
🔸Safety profile: The vaccine was found to be safe even with repeated doses.
These results, reported by the Russian news agency TASS, mark one of the most promising advancements in cancer treatment in recent years.
Also Read: https://skylinktimes.in/rare-mycetia-malayana-spotted-in-tripura/
Targeted Cancers: Colorectal, Brain, and Skin
The first clinical application of Enteromix will focus on colorectal cancer, a common and deadly cancer affecting the large intestine.
In addition, researchers are developing variants of the vaccine for:
Glioblastoma – an aggressive brain cancer.
Melanoma – a serious form of skin cancer, including ocular melanoma that affects the eye.
A Global Breakthrough With Worldwide Implications
The announcement drew attention at the Eastern Economic Forum, which hosted over 8,400 participants from 75 countries. Experts believe that if Enteromix succeeds in clinical use, it could become a game-changer in oncology, much like mRNA vaccines transformed the global response to COVID-19.
While Enteromix still requires human clinical trials before global approval, the FMBA’s findings have sparked hope for millions battling cancer worldwide.
Conclusion
With its mRNA foundation, promising trial results, and focus on deadly cancers, Enteromix represents a major stride in cancer research. If further trials confirm its effectiveness, this vaccine could redefine cancer treatment and prevention in the coming decade.
For More Info Stay Tuned: https://skylinktimes.in
